Genflow Biosciences PLC (LSE: GENF)

(LSE: GENF) is an FTSE listed, based in the United Kingdom, is a biotechnology company focused on developing gene therapies aimed at slowing the aging process and reducing age-related diseases. Its approach involves using adeno-associated virus (AAV) vectors to deliver the Sirtuin-6 (SIRT6) gene variant — identified in centenarians — into human cells to promote healthier aging. This Report covers the Key Recommendation Rationale, Conclusion, and Recommendation on the stock.

Key Recommendation Rationale – Sell at GBX 2.38

• Resistance near Current levels: GENF’s stock price has approached Resistance (R1) which was stated in the previous report on 16 October 2025 therefore, there can be a possibility of a decline from resistance levels. Considering the market conditions and the price action, it is prudent to exit the stock.
• Limited Financial Reserves May Constrain Development Pace - As of 30 June 2025, Genflow reported cash reserves of approximately £279,000, which, while slightly increased from year-end 2024, remains modest for a biotech company with multiple early-stage programs. Despite successful equity fundraising in the first half, the current cash position could restrict the Company’s ability to progress several parallel pipelines without further capital injections. This places additional reliance on securing timely non-dilutive funding or raising further equity, which may introduce uncertainty around project timelines or shareholder dilution.
• Preclinical and Early-Stage Focus Limits Near-Term Revenue Visibility - While Genflow’s science-driven approach and dual human-animal pipeline are strategically aligned, most of its programs remain at either the preclinical or proof-of-concept stage. With no therapies yet in clinical trials for humans and animal health studies still in early phases, revenue generation remains a longer-term prospect. For investors focused on near-term monetisation or commercial validation, this early-stage positioning may limit visibility on potential returns over the short to medium term.

Share Price Chart  

GENF Daily Technical Chart, Source - Refinitiv 

Conclusion

Given its current trading levels, Preclinical and Early-Stage Focus Limits Near-Term Revenue Visibility, recent rally in the share price, relative valuation, and associated risks, it is prudent to exit the stock at the current levels. Hence, a ‘Sell’ recommendation is given on the stock at the Current Market Price of GBX 2.38 as of 22 October 2025 at 10:55 AM GMT+1.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is 22 October 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level which the stock is expected to reach as per the relative valuation method and/or technical analysis taking into consideration both short-term and long-term scenario.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the London Stock Exchange (LSE) and/or REFINITIV. Typically, both sources (LSE and or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.’

Note 6: Dividend Yield may vary as per the stock price movement.